Leukemia penia resolved. Because of clinical evolutivity and further IgG concentration increase, the anti-CD20 chimeric monoclonal antibody Rituximab (Mabthera, Roche, Basel, Switzerland) was administered at 375 mg/m 2 /week for 4 weeks. Polyadenopathy and PB plasma cells progressively disappeared. Serum IgG and LDH returned to normal values within 2 months. A BM biopsy performed at that time showed disappearance of B cell immunoblasts and normal plasma cells. Neutropenia did not relapse despite persistence of anti-neutrophils antibodies. Nine months after Rituximab therapy, the patient is in complete remission.
Expression of CD133 on a human cell line lacking CD34
− cell population and their identification has been hampered by the laborious isolation procedure and the small yield of cells obtained by the various methods of isolation used so far. Therefore, a priority is to search for cell lines with HSC characteristics in order to facilitate research in this area.
In 1994, we established a new fibroblast like cell line, designated GM-490, from the bone marrow of a patient with acute lymphoblastic leukaemia. 5 GM-490 cells have a morphology typical of adherent fibroblasts. GM-490 cells express CD29, CD36, CD71, CD54, CD105 surface antigens but lack CD34, CD38, HLA-DR, CD45, CD14 and all lymph-
Figure 1
A GM-490 cell sample was stained with CD133(PE) and CD34(FITC). Cellular debris was gated out on the basis of light scatter (a). A total of 10 000 events was acquired. Quadrants were defined by using appropriate isotypic control Mabs (b). Virtually all (98%) GM-490 cells express CD133, but not CD34 (c).
oid and myeloid markers. More recently, we have found that a majority of GM-490 cells expresses CD133 (Figure 1 ). Up to now, only four human cell lines express CD133: two retinoblastoma (WeriRb-1,Y79), one teratocarcinoma (NT2) and one monocytic leukaemia (MUTZ-2) cell line.
GM-490 is the first known human hematopoietic cell line which expresses CD133 lacking CD34 antigen. It represents a useful model to study the hierarchy of HSC. Studies are in progress in our laboratory in order to induce GM-490 cell differentiation towards hematopoietic and endothelial progenitors. 
